MKI67 and non-small cell lung carcinoma: The bona fide validity of Ki-67 in predicting response to systemic and endocrine agents is evident in modern practice [85,108,109]; however, recent analyses suggest proliferative markers, including Ki-67, may be predictive of resistance to immune checkpoint inhibition in NSCLC [110].